A higher selectivity of THZ1 in PTCL compared with actinomycin or others CDK7 inhibitors could be due to the high expression of CDK7 in PTCLs and by the specific and covalent binding of THZ1 to CDK7 (ref. 9). The gene discussed is CDK7; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.